CN107106708B - 使用脂质体进行的淀粉样蛋白斑mri成像 - Google Patents

使用脂质体进行的淀粉样蛋白斑mri成像 Download PDF

Info

Publication number
CN107106708B
CN107106708B CN201580066712.6A CN201580066712A CN107106708B CN 107106708 B CN107106708 B CN 107106708B CN 201580066712 A CN201580066712 A CN 201580066712A CN 107106708 B CN107106708 B CN 107106708B
Authority
CN
China
Prior art keywords
phospholipid
polymer
liposomal composition
aromatic
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580066712.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107106708A (zh
Inventor
A·安娜普拉戈达
E·A·塔尼芬
M·斯里瓦斯塔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Childrens Hospital
Original Assignee
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Childrens Hospital filed Critical Texas Childrens Hospital
Publication of CN107106708A publication Critical patent/CN107106708A/zh
Application granted granted Critical
Publication of CN107106708B publication Critical patent/CN107106708B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580066712.6A 2014-10-08 2015-10-08 使用脂质体进行的淀粉样蛋白斑mri成像 Active CN107106708B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US62/061,514 2014-10-08
US201562111057P 2015-02-02 2015-02-02
US62/111,057 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (2)

Publication Number Publication Date
CN107106708A CN107106708A (zh) 2017-08-29
CN107106708B true CN107106708B (zh) 2021-06-18

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580066712.6A Active CN107106708B (zh) 2014-10-08 2015-10-08 使用脂质体进行的淀粉样蛋白斑mri成像

Country Status (10)

Country Link
US (4) US9744251B2 (https=)
EP (3) EP3204051B1 (https=)
JP (1) JP6505235B2 (https=)
KR (1) KR102409017B1 (https=)
CN (1) CN107106708B (https=)
AU (2) AU2015330824A1 (https=)
CA (1) CA2963941C (https=)
ES (2) ES2743704T3 (https=)
MX (1) MX371295B (https=)
WO (1) WO2016057812A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012139080A2 (en) 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
CA2848994A1 (en) 2012-01-20 2013-07-25 Ananth Annapragada Methods and compositions for objectively characterizing medical images
EP3204051B1 (en) 2014-10-08 2019-05-29 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
KR102472003B1 (ko) 2016-07-22 2022-11-29 에이씨 이뮨 에스에이 타우 단백질 응집체를 이미징하기 위한 화합물
EP3512570B1 (en) * 2016-09-16 2024-08-28 Texas Children's Hospital Liposomal gadolinium (gd) contrast agent for t1-mri
US11241510B2 (en) 2016-11-30 2022-02-08 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19F MRI probes with unique MR signatures
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
US20210041447A1 (en) 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
CN116173238A (zh) * 2018-03-29 2023-05-30 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
WO2019234243A1 (en) 2018-06-08 2019-12-12 Ac Immune Sa Novel compounds for diagnosis
JP7545393B2 (ja) * 2019-01-24 2024-09-04 アルゼカ バイオサイエンシズ、エルエルシー 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
US20210128755A1 (en) * 2019-07-08 2021-05-06 Alzeca Biosciences, LLC Targeting ligands for tau pathology
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
CN115916263B (zh) * 2020-01-29 2025-10-03 德克萨斯儿童医院 用于淀粉样蛋白沉积mri的靶向对比剂
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115279424A (zh) * 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
DE69527194T2 (de) 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
WO2004096120A2 (en) * 2003-05-01 2004-11-11 Nst Neurosurvival Technologies Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US20070292354A1 (en) 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
WO2007041855A1 (en) 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
WO2009015397A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
US8642013B2 (en) 2007-12-05 2014-02-04 Ananth Annapragada Nano-scale contrast agents and methods of use
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN102438591A (zh) 2009-03-19 2012-05-02 马维尔生物科学公司 用于增强成像对比度的组合物和方法
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
CN103429226A (zh) 2011-03-02 2013-12-04 森苏林公司 囊泡组合物
WO2012139080A2 (en) * 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA2848994A1 (en) 2012-01-20 2013-07-25 Ananth Annapragada Methods and compositions for objectively characterizing medical images
US9377472B2 (en) 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP3204051B1 (en) 2014-10-08 2019-05-29 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
WO2016057812A1 (en) 2016-04-14
EP3204051A4 (en) 2018-06-27
US9744251B2 (en) 2017-08-29
MX371295B (es) 2020-01-24
AU2021203388A1 (en) 2021-06-24
US11141495B2 (en) 2021-10-12
US20160101197A1 (en) 2016-04-14
CN107106708A (zh) 2017-08-29
JP6505235B2 (ja) 2019-04-24
EP3204051B1 (en) 2019-05-29
US20170080111A1 (en) 2017-03-23
KR20170103748A (ko) 2017-09-13
HK1243335A1 (zh) 2018-07-13
ES3032054T3 (en) 2025-07-15
US20200179540A1 (en) 2020-06-11
EP4035688C0 (en) 2025-03-26
ES2743704T3 (es) 2020-02-20
AU2015330824A1 (en) 2017-05-25
KR102409017B1 (ko) 2022-06-16
AU2021203388B2 (en) 2024-05-30
US20200069820A1 (en) 2020-03-05
EP4035688B1 (en) 2025-03-26
EP4035688A1 (en) 2022-08-03
JP2017532378A (ja) 2017-11-02
CA2963941C (en) 2023-08-01
BR112017007238A2 (pt) 2018-01-16
CA2963941A1 (en) 2016-04-14
US10537649B2 (en) 2020-01-21
EP3204051A1 (en) 2017-08-16
EP3542828A1 (en) 2019-09-25
MX2017004695A (es) 2018-01-24

Similar Documents

Publication Publication Date Title
CN107106708B (zh) 使用脂质体进行的淀粉样蛋白斑mri成像
Tanifum et al. A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging
Moussaron et al. Ultrasmall nanoplatforms as calcium‐responsive contrast agents for magnetic resonance imaging
KR102035187B1 (ko) 지질-기반 나노입자들
JP5897461B2 (ja) ミエリン塩基性タンパク質のイメージング
JP7114074B2 (ja) 画像化のためのニトロキシドを含むアミロイド結合剤およびその治療的使用
Kim et al. An aptamer‐based magnetic resonance imaging contrast agent for detecting oligomeric amyloid‐β in the brain of an Alzheimer's disease mouse model
Li et al. Detection of Aβ Plaques by a Novel Specific MRI Probe Precursor CR‐BSA‐(Gd‐DTPA) n in APP/PS1 Transgenic Mice
JP7545393B2 (ja) 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
HK40010427A (en) Mri imaging of amyloid plaque using liposomes
HK1243335B (zh) 使用脂质体进行的淀粉样蛋白斑mri成像
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides
US20230136718A1 (en) Functionalized liposomes for imaging misfolded proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243335

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant